MiMedx Group, Inc. Net Change in Cash
MiMedx Group, Inc. (MDXG) reported Net Change in Cash of -$30.28 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-07-29
- MiMedx Group, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$6.35M, a 415.04% decline year-over-year.
- MiMedx Group, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was $2.02M.
- MiMedx Group, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$33.51M.
- MiMedx Group, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$4.73M.
- MiMedx Group, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $61.70M, a 175.27% increase from fiscal 2024.
- MiMedx Group, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was $22.42M, a 39.66% increase from fiscal 2023.
- MiMedx Group, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was $16.05M.
- MiMedx Group, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$21.13M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$30.28M 10-Q · filed 2026-07-29 | |||
| 2026-03-31 | -$6.35M 10-Q · filed 2026-04-29 | |||
| 2025-12-31 | $61.70M 10-K · filed 2026-02-25 | |||
| 2025-09-30 | $37.67M 10-Q · filed 2025-10-29 | |||
| 2025-06-30 | $14.45M 10-Q · filed 2026-07-29 | |||
| 2025-03-31 | $2.02M 10-Q · filed 2026-04-29 | |||
| 2024-12-31 | $22.42M 10-K · filed 2026-02-25 | |||
| 2024-09-30 | $6.80M 10-Q · filed 2025-10-29 | |||
| 2024-06-30 | -$12.96M 10-Q · filed 2025-07-30 | |||
| 2024-03-31 | -$33.51M 10-Q · filed 2025-04-30 | |||
| 2023-12-31 | $16.05M 10-K · filed 2026-02-25 | |||
| 2023-09-30 | $15.21M 10-Q · filed 2024-10-30 | |||
| 2023-06-30 | $2.70M 10-Q · filed 2024-07-31 | |||
| 2023-03-31 | -$4.73M 10-Q · filed 2024-04-30 | |||
| 2022-12-31 | -$21.13M 10-K · filed 2025-02-26 | |||
| 2022-09-30 | -$13.87M 10-Q · filed 2023-10-30 | |||
| 2022-06-30 | -$14.58M 10-Q · filed 2023-08-01 | |||
| 2022-03-31 | -$11.41M 10-Q · filed 2023-05-02 | |||
| 2021-12-31 | -$8.73M 10-K · filed 2024-02-28 | |||
| 2021-09-30 | -$5.21M 10-Q · filed 2022-11-02 | |||
| 2021-06-30 | -$10.80M 10-Q · filed 2022-08-02 | |||
| 2021-03-31 | -$11.07M 10-Q · filed 2022-05-03 | |||
| 2020-12-31 | $26.74M 10-K · filed 2023-02-28 | |||
| 2020-09-30 | $40.53M 10-Q · filed 2021-11-02 | |||
| 2020-06-30 | -$20.88M 10-Q · filed 2021-08-03 | |||
| 2020-03-31 | -$15.54M 10-Q · filed 2021-04-28 | |||
| 2019-12-31 | $23.95M 10-K · filed 2022-02-28 | |||
| 2019-09-30 | $49.00M 10-Q · filed 2020-11-04 | |||
| 2019-06-30 | $51.81M 10-Q · filed 2020-08-04 | |||
| 2019-03-31 | -$16.74M 10-Q · filed 2020-07-06 | |||
| 2018-12-31 | $17.64M 10-K · filed 2021-03-08 | |||
| 2018-09-30 | $17.58M 10-Q · filed 2020-07-06 | |||
| 2018-06-30 | $16.86M 10-Q · filed 2020-07-06 | |||
| 2018-03-31 | -$1.02M 10-Q · filed 2020-07-06 | |||
| 2017-12-31 | -$2.85M 10-K · filed 2020-07-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B | |
| SS Innovations International, Inc. (SSII) | $0.589B | -64.06 | |
| DELCATH SYSTEMS, INC. (DCTH) | United States | $0.558B | 820.33 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| CERUS CORP (CERS) | United States | $0.525B | -86.40 |
| TACTILE SYSTEMS TECHNOLOGY INC (TCMD) | United States | $0.519B | 27.16 |
| NeuroPace Inc (NPCE) | United States | $0.480B | -28.52 |
| Sight Sciences, Inc. (SGHT) | United States | $0.478B | -9.95 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B |